Smart Biopsy Devices Global Market Report 2024

The smart biopsy devices market size has grown strongly in recent years. It will grow from $2.73 billion in 2023 to $2.93 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth observed in the historical period can be attributed to factors such as the increased incidence of cancer cases, a growing demand for minimally invasive procedures, innovations in medical devices, and improvements in diagnostic accuracy.

The smart biopsy devices market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to the expansion of personalized medicine, advancements in imaging modalities, an increase in biopsies for biomarker analysis, the entry of new players into the market, and enhanced data connectivity. Key trends expected in the forecast period encompass robot-assisted biopsies, AI-driven biopsy assistance, the development of wireless biopsy tools, the emergence of portable and handheld devices, and the implementation of real-time guidance systems.

The growth of the smart biopsy devices market is anticipated to be propelled by the increasing incidence of cancer. Cancer, a diverse group of diseases characterized by uncontrolled cell growth, has led to a rising demand for precise tissue samples. This has stimulated the development and advancement of smart biopsy instruments equipped with enhanced molecular, imaging, and precision capabilities to aid in the diagnosis and planning of cancer treatment. Notably, in October 2022, the Australian Institute of Health and Welfare reported a rise in newly diagnosed cancer cases in Australia, reaching 1.58 million in 2021, compared to 1.54 million in 2020. Hence, the upsurge in cancer cases is a driving force behind the growth of the smart biopsy device market.

The adoption of minimally invasive procedures is poised to contribute significantly to the growth of the smart biopsy devices market. Minimally invasive procedures, designed to minimize disruption to the body's normal structures, benefit from the use of smart biopsy devices to enhance precision and accuracy in tissue sampling. These devices often incorporate advanced imaging technologies such as real-time ultrasound or MRI guidance, enabling healthcare professionals to target specific areas for biopsy through smaller incisions. This reduces patient trauma and enhances diagnostic accuracy. For instance, data from the Organization for Economic Co-operation and Development in October 2023 revealed an 8.4% increase in cataract surgical procedures in the Czech Republic, totaling 142,670 procedures in 2022 compared to 131,612 in 2021. Therefore, the growing adoption of minimally invasive procedures is a driving factor in the smart biopsy devices market.

Technological innovation has become a prominent trend in the smart biopsy devices market, with major companies focusing on developing innovative products to strengthen their market positions. An example is the launch of the Quick-Core Auto Biopsy System by IZI Medical Products LLC in April 2021. This fully automatic biopsy system enhances the efficiency and reliability of soft tissue biopsies, maintaining the high standards set by IZI's semi-automatic Quick-Core biopsy device. The portable system is lightweight and compact, allowing for one-handed use during procedures.

Major companies in the smart biopsy devices market are introducing new products, such as dual-stage core biopsy instruments, to gain a competitive advantage. Dual-stage core biopsy involves a two-step process, starting with the acquisition stage, where the biopsy instrument is guided to obtain a tissue sample, followed by the extraction stage to retrieve the obtained tissue for diagnostic analysis. For instance, Mammotome, a breast cancer care solutions company, launched the Mammotome DualCore Dual Stage Core Biopsy System in August 2022. This advanced system offers three programmable firing modes and one-handed operation, providing clinicians with a versatile tool for accessing challenging lesions. The system's ergonomic design minimizes needle movements and vibrations, enhancing the overall patient experience.

In June 2023, Quest Diagnostics, a medical laboratories company, acquired Haystack Oncology for $450 million. This strategic acquisition enhances Quest Diagnostics' cancer diagnostics portfolio by incorporating Haystack's highly sensitive minimal-residual disease (MRD) testing technology based on circulating tumor DNA (ctDNA). The addition of Haystack's advanced testing capabilities allows Quest to offer improved early detection of solid tumor cancers through blood-based clinical lab services, starting in 2024. Haystack Oncology Inc. specializes in developing and utilizing advanced technologies for MRD testing in the field of cancer diagnostics.

Major companies operating in the smart biopsy devices market report are Cardinal Health Inc., General Electric Company, Medtronic PLC, Danaher Corporation, Canon Medical Systems Corporation, Toshiba Corporation, Siemens Healthineers, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., Becton Dickinson and Company, Boston Scientific Corporation, B. Braun AG, Olympus Corporation, Intuitive Surgical Inc., Hologic Inc., Cook Medical Inc., CONMED Corporation, Leica Biosystems, Argon Medical Devices Inc., Esaote SpA, SOMATEX Medical Technologies GmbH, Planmed Oy, TSK Laboratory Europe B.V., ZAMAR CARE, DTR Medical Ltd., INRAD Inc., Sterylab Srl, EndoMed Systems GmbH.

North America was the largest region in the smart biopsy devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the smart biopsy devices market report during the forecast period. The regions covered in the smart biopsy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart biopsy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products within the category of smart biopsy devices include needle-based biopsy instruments, procedure trays, localization wires, and others. Needle-based biopsy instruments are tools used to extract a sample of the body's cells for laboratory analysis, collecting tissue or liquid samples from various organs such as bones, muscles, liver, and lungs. These devices employ guidance techniques such as ultrasound-guided biopsy, stereotactic-guided biopsy, magnetic resonance imaging-guided biopsy, and others. Smart biopsy devices find applications in various areas, including breast cancer, skin cancer, liver cancer, prostate cancer, and more. The end users of these devices include hospitals, academic and research institutes, as well as diagnostic and imaging centers.

The smart biopsy devices research report is one of a series of new reports that provides smart biopsy devices market statistics, including the smart biopsy devices industry's global market size, regional shares, competitors with smart biopsy devices market share, detailed smart biopsy devices market segments, market trends and opportunities, and any further data you may need to thrive in the smart biopsy devices industry. This smart biopsy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The smart biopsy devices market consists of revenues earned by entities by providing services such as collecting biopsy samples, real-time cancer tissue characterization, minimally invasive biopsy, and precise tissue targeting. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart biopsy devices market also includes sales of image-guided biopsy devices, core biopsy devices, bone biopsy needles and devices, and molecular biopsy devices which are used in providing collecting biopsy samples, real-time cancer tissue characterization services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.